Don’t miss this interview with two co-authors of the ‘IMROZ’ study, the first global Phase III study of an anti-CD38 monoclonal antibody delivered in combination with the standard of care VRd (triplet combination of bortezomib, lenalidomide, dexamethasone) in patients with newly diagnosed multiple myeloma not intended for transplant. Results show an improvement in progression-free survival, with consistent responses, supporting the frontline use of Isa-VRd in patients not intended for transplant.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given